ClinicalTrials.gg
CompletedNCT02064556CKD-330(A)Updated Aug 15, 2014

CKD-330 Drug-Drug Interaction Study (Amlodipine)

A Phase 1 interventional study of Amlodipine 10mg and Amlodipine 10mg/Candesartan 32mg in Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
172nd of 186
24 · median 180
Started
2014
with 11 others
Phase 1
17 of 187
none open now
Registered
119th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 172nd largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 17 in phase 1, and was the 119th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of Amlodipine between free combination of Amlodipine and Candesartan and Amlodipine monotherapy.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteer is between 20 and 45 years of age(inclusive) at the pre-study(screening).
  2. Volunteer who has 19kg/m² ≤ (Body Mass Index) ≤ 26kg/m²
  3. When volunteer in screening, Must include under the items.

    1. 100 mmHg ≤ sitting SBP \<140 mmHg
    2. 60 mmHg ≤ sitting DBP \< 90 mmHg
    3. 45 bpm ≤ Pulse \< 95 bpm
  4. Those who decided to join the clinical trials by themselves and to comply with the precautions written consent.

Exclusion criteria

Exclusion Criteria:

  1. A previous history or present of liver, renal, gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, cardiovascular disease.
  2. Have a gastrointestinal disease history that can affect drug absorption(Crohn's disease, Ulcers, GERD, Gastritis, etc.) or surgery (except simple appendectomy or hernia surgery).
  3. The history of clinically significant reaction about drugs and foods.
  4. The history of drug abuse or drug abuse showed a positive for urine drug test.
  5. Taking drugs have received any other investigational drug within 90 days prior to the first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing.
  6. Whole blood donation within 60 days prior to the first dosing or plasma donation within 30 days prior to the first dosing.
  7. Taking drugs that clinical trials expected to affect within 14days or taking food containing caffeine, grapefruit within 7days before the first dosing.
  8. A heavy alcohol consumer(alcohol>3cup/day or 3times/week within last 1month)
  9. A heavy smoker(cigarette>10cigarettes/day)
  10. The subject has positive results of serum tests(, C, Test, Syphilis).
  11. Have the Liver enzyme levels(, ALT) or , total results greater than 1.5 times the UNL.
  12. Have the result of is less than 80mL/min(Cockcroft-Gault equation applicable).
  13. The result of 12-lead in screening test is >450msec.
  14. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    A(Amlodipine 10mg)

    Amlodipine 10mg 1T, PO, QD for 9days

    Drug: Amlodipine 10mg/Candesartan 32mg

  • Experimental
    B(Amlodipine 10mg/Candesartan 32mg)

    Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days

    Drug: Amlodipine 10mg

Interventions

  • Amlodipine 10mg 1T, PO, QD for 9days

    Also known as: Norvasc Tab. 10mg

  • DrugAmlodipine 10mg/Candesartan 32mg

    Drug page: Amlodipine

    Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days

    Also known as: Norvasc Tab. 10mg/Atacand Tab. 32mg

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of Amlodipine

    Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h

  2. Cmax,ss of Amlodipine

    Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h

Secondary outcomes

  1. Tmax,ss of Amlodipine

    Time frame: 1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Songpa-gu, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 17, 2014
Start
May 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Aug 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02064556
Responsible party
Sponsor
First posted
Feb 17, 2014
Start date
May 2014
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Aug 15, 2014

Study contacts

Kyun-Seop Bae, Professor
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion